All articles

Bimagrumab and myostatin blockers: muscle, fat, and what the studies showed

Muscle, fat and what the studies showed

What it is

Myostatin is a protein that holds back muscle growth.

  • it works as a "brake" for muscle
  • drugs of this class weaken it
  • the idea: let muscle grow

How the drugs work

Some close the "lock", others catch the signal itself.

  • bimagrumab closes the receptor
  • other drugs bind the protein itself
  • that is why their results differ

What happens to the body

There is more muscle and less fat.

  • in studies muscle mass grows
  • fat mass goes down
  • body composition changes more than weight

Weight and body composition

Weight on the scale and body composition are different things.

  • during weight loss part of the weight comes from muscle
  • on bimagrumab muscle did not shrink in studies
  • that is why combining it with weight-loss drugs is discussed

Strength and muscle mass

More muscle does not always mean more strength.

  • mass grew in studies
  • walking and strength tests behaved differently
  • strength also depends on nutrition and training

Age and falls

For older people the main thing is to walk and not fall.

  • muscle gained mass after surgery
  • walking recovered the same as without the drug
  • falls did not become fewer

Movement and nutrition

Protein and exercise remain the foundation.

  • in studies everyone received nutrition and exercise
  • function improved even without the drug
  • this is the most reliable part

Rare muscle diseases

There are diseases where muscles weaken because of a gene or inflammation.

  • in many of them no benefit for walking and strength was found
  • several programs were closed
  • expectations of the class should be kept level

The approved indication

One drug is approved: for a rare disease in which muscles weaken.

  • it is spinal muscular atrophy
  • it is added to the main treatment in children from age 2 and adults
  • nothing is approved for gaining muscle or for "youth"

Side effects

The drug acts not only on muscle.

  • frequent cramps and loose stools
  • acne occurs
  • cholesterol changes

Bone and glands

By weakening one signal, others can be affected.

  • one drug has a fracture warning in its label
  • the drug affects other hormones too
  • that is why a doctor and monitoring are needed

Who should see a doctor first

There are cases when you cannot do without a doctor.

  • fractures and weak bones
  • pregnancy and breastfeeding
  • the youngest children

Important. Such a drug is prescribed only by a doctor after an examination and tests.

The main thing

The drugs change body composition, and the test result is a separate question.

  • muscle grows, fat goes
  • strength and function behaved differently
  • one rare indication is approved
  • the decision is made by a doctor

Frequently asked questions

It is a human antibody that blocks type II activin receptors and in this way removes the limit on muscle growth. In studies of people with obesity it reduced fat mass and preserved lean mass: lean mass +1.0…+1.1 % on bimagrumab versus −4.7…−6.9 % on semaglutide (BELIEVE, 507 people, 1 study). It is not listed in Drugs@FDA and is not registered.

One: apitegromab (Isembyld), approved by the FDA on 11.09.2026 for spinal muscular atrophy in adults and children from age 2 who already receive therapy aimed at the SMN2 gene. The dose is 10 mg/kg intravenously every 4 weeks (FDA label).

Mass grew, but test results did not differ significantly from placebo. In a study of 180 people lean mass was +7 % versus +1 %, the Short Physical Performance Battery (SPPB) was +1.34 versus +1.03 points (P = 0.13), and function improved in both groups.

Semaglutide 2.4 mg lowers weight more on its own: −14.2 kg versus −9.3 kg on bimagrumab 30 mg/kg over 48 weeks (507 people, 1 study), but lean mass goes down along with fat (−4.7…−6.9 %). On bimagrumab lean mass did not fall, while glycated hemoglobin (HbA1c) dropped less: −0.23 % (≈ −2.5 mmol/mol) versus −0.40 % (≈ −4.4 mmol/mol) by week 72.

Muscle spasms, diarrhea and acne. In a meta-analysis of four studies (268 people) the relative risk was 10.44 for muscle spasms and 4.91 for diarrhea, and low-density lipoprotein cholesterol rose by 0.47 mmol/L (≈ 18 mg/dL). In BELIEVE, treatment was stopped because of adverse events by 14.0–21.4 % on bimagrumab alone versus 3.6 % on placebo.

In the apitegromab label fractures are a warning: 9 % on 10 mg/kg and 6 % on 20 mg/kg versus 2 % on placebo (53 people per group), and 22 people (9 %) in the extension. In BELIEVE hip bone density fell by 2.0–2.3 % on semaglutide and the combinations versus 0.8 % on placebo (56–57 people per group).

No drug of the class is registered for gaining muscle. The studies enrolled people with obesity, sarcopenia and muscle diseases; a study of 68 healthy people aged 60–86 assessed heart safety over 6 months.

The combination of bimagrumab with semaglutide was studied in one phase 2 study (507 people): −17.8 kg over 48 weeks on the combination of high doses versus −14.2 kg on semaglutide 2.4 mg. The authors note that there was no adjustment for multiple comparisons and the result should not be considered final.

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question